<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526643</url>
  </required_header>
  <id_info>
    <org_study_id>CAPPA-2</org_study_id>
    <secondary_id>2005-005631-97</secondary_id>
    <nct_id>NCT00526643</nct_id>
  </id_info>
  <brief_title>CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients</brief_title>
  <acronym>CAPPA-2</acronym>
  <official_title>Gemcitabine Versus Cisplatin and Gemcitabine in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer in Poor Physical Condition (Performance Status 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trials Promoting Group (APRIC/CTPG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Oncologico del Lazio (GOL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Oncologico Italiano di Ricerca Clinica(GOIRC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gruppo Oncologico Italia Meridionale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwest Oncology Cooperative Group(GONO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the impact on overall survival (OS) of the
      addition of cisplatin to gemcitabine vs gemcitabine alone in patients with advanced NSCLC in
      poor clinical condition (PS 2), not previously treated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Performance status is one of the most important prognostic factors for patients with advanced
      non-small cell lung cancer (NSCLC), regardless of treatment received. Chemotherapy is
      recommended for advanced NSCLC patients in good clinical condition, but it is not clear how
      much benefit is gained from giving chemotherapy to patients in poor general condition
      (performance status 2). This category of patients represents about 20% of all patients at
      initial diagnosis of NSCLC, and remains a treatment challenge for the clinician. There have
      been very few studies that have evaluated the impact of chemotherapy for this group of
      patients, and there is no established standard therapy. Studies evaluating single agent and
      combination two-agent chemotherapy regimens' impact on survival and improving symptoms are
      needed.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    scarce enrolment and presentation of positive results of similar study in June 2012.
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in performance status</measure>
    <time_frame>each cycle of chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>each cycle of chemotherapy and every 3 months thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>chemotherapy cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response</measure>
    <time_frame>at 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>monochemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin 60 mg/m2 on day 1 for 4 cycles</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of advanced non small cell lung
             cancer, not amenable to surgical or curative radiation therapy (stage IIIB or IV);

          -  No prior or concomitant chemotherapy (adjuvant/neoadjuvant chemotherapy permitted if
             concluded at least one year prior to enrollment);

          -  ECOG performance status 2;

          -  Age: &gt; or = 18 and &lt; 70 years;

          -  Life expectancy at least 4 weeks;

          -  Normal bone marrow, hepatic and renal function defined as: neutrophils &gt; or =
             2000/mm3, PLT &gt; or = 100,000/mm3, Hb &gt; or = 10.0 g/dl, Bilirubin &gt; or = 1.5 times the
             upper normal limit (UNL), AST and ALT &lt; or = 3 times the UNL (5 times in the presence
             of liver metastases), creatinine within normal limits;

          -  Signed informed consent.

        Exclusion Criteria:

          -  Active systemic infections;

          -  Severe concomitant illness (congestive heart failure, angina pectoris, myocardial
             infarction within previous 6 months, cardiac arrhythmias under treatment, severe
             arterial hypertension, severe or uncontrolled diabetes mellitus);

          -  Inadequate hepatic or renal function;

          -  Radiation therapy ongoing or concluded within two weeks prior to enrollment;

          -  Symptomatic cerebral metastases;

          -  Previous chemotherapy for advanced disease;

          -  Any condition that would, in the investigator's opinion, limit the patients ability to
             provide informed consent or to comply with study procedures;

          -  Pregnant or nursing females;

          -  Any malignancy within the past 5 years (except for adequately treated carcinoma in
             situ of the cervix or non melanoma skin cancer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesare Gridelli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>APRIC/CTPG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luciano Frontini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vittorio Gebbia, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gruppo Oncologico Italia Meridionale</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Ardizzoni, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gruppo Oncologico Italiano di Ricerca Clinica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filippo de Marinis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>GOL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrico Aitini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gruppo Oncologico del Nord-Ovest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Giuseppe Moscati, U.O. di Oncologia Medica</name>
      <address>
        <city>Monteforte Irpino</city>
        <state>AV</state>
        <zip>83024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Miulli, Divisione Medicina Interna Sezione Oncologica</name>
      <address>
        <city>Acquaviva delle Fonti</city>
        <state>BA</state>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico di Bari, U.O. di Oncologia Medica e Sperimentale</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico S. Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera C. Poma</name>
      <address>
        <city>Mantova</city>
        <state>MN</state>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale E. Morelli</name>
      <address>
        <city>Sondalo</city>
        <state>SO</state>
        <zip>23039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Senatore Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Mater Domini, Oncoematologia Università Magna Grecia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale F. Veneziale</name>
      <address>
        <city>Isernia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regional, Unità Operative di Oncologia</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Camillo - Forlanini</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Felice a Cancello</name>
      <address>
        <city>San Felice a Cancello</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Morabito A, Gebbia V, Di Maio M, Cinieri S, Viganò MG, Bianco R, Barbera S, Cavanna L, De Marinis F, Montesarchio V, Costanzo R, Sandomenico C, Montanino A, Mancuso G, Russo P, Nacci A, Giordano P, Daniele G, Piccirillo MC, Rocco G, Gridelli C, Gallo C, Perrone F. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer. 2013 Jul;81(1):77-83. doi: 10.1016/j.lungcan.2013.04.008. Epub 2013 May 1.</citation>
    <PMID>23643177</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2007</study_first_submitted>
  <study_first_submitted_qc>September 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB</keyword>
  <keyword>Stage IV</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>monotherapy</keyword>
  <keyword>combination chemotherapy</keyword>
  <keyword>poor performance status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

